Trial Profile
An Open-label, Phase I Study to Assess the Safety of NKR-2 Treatment Administered Concurrently With 5-azacytidine in Treatment-naïve Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients Not Candidates for Intensive Therapy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; CYAD 01 (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Acronyms EPITHINK
- Sponsors Celyad Oncology
- 04 Sep 2023 Results presented in The Lancet Haematology Journal.
- 04 Nov 2020 According to a Celyad Oncology SA media release, abstract from this study has been accepted for presentation at the virtually held 62nd American society of Hematology (ASH) Annual meeting and exposition.(Publication 993)
- 25 Oct 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.